Kintor's March 2026 annual-results disclosure reported topline data from the 666-patient Phase 3 stage of its China pivotal trial; company says it will file an NDA with China's NMPA soon.
- Lab
- Phase 1
- Phase 2
- Phase 3
- Approved
Phase 3
How it works
Topical androgen receptor antagonist applied to the scalp to block DHT signalling locally without significant systemic absorption.
Results so far
Target area hair count improved 15.33 hairs/cm2 (1.0% dose) and 14.46 hairs/cm2 (0.5% dose) vs 4.68 hairs/cm2 for placebo; no drug-related serious adverse events reported (press-release figures, not yet in a peer-reviewed paper).
What's next
NDA filing with China's NMPA described as imminent as of early 2026; no FDA filing announced.
In India
No India-specific development or CDSCO filing identified in this research.
Sources
- News report ↗ (accessed 2026-10-17)
- News report ↗ (accessed 2026-10-17)
- Trial registry ↗ (accessed 2026-10-17)
- Trial registry ↗ (accessed 2026-10-17)
What to do today: treatments in development aren't a reason to wait. Ask a dermatologist about the options that work now, such as minoxidil and, for men, finasteride.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.